Blood Test Detects Oropharyngeal Cancer Recurrence

A simple blood test may be able to notify patients and their health care providers if their oropharyngeal cancer is recurring.
A recent study conducted at the University of Michigan Health System found that a blood test can detect the recurrence of oropharyngeal cancer.
Oropharyngeal cancer occurs in throat, tonsils and back of the tongue. It is often connected to the human papilloma virus (HPV), which usually makes the cancer more responsive to treatment. However, in about 15 to 20 percent of patients, the cancer returns because the treatment failed, which cannot be detected through biomarkers.
However, this new study found that recurrence can be detected in its early stages by tracking patients’ antibody levels. Participants in the study who experienced recurrence of oropharyngeal cancer had higher levels of antibodies for two proteins found in HPV-related cancers, E6 and E7.
For the study, researchers looked at information collected for a previous study involving 52 patients with HPV-related advanced oropharyngeal cancer. Out of the participants, who were all similar in age, cancer classification and smoking status, 22 had developed recurrence and 30 had not.
Participants’ serum was evaluated through a blood test at the start of treatment, after treatment ended and every three months after that. Those who had a recurrence were diagnosed within three months of the blood samples used for the study. On average, a patient was diagnosed with a recurrence thirteen months after their treatment ended.
Soon after treatment, patients with recurrence and patients without had no difference in E6 and E7 antibody levels. All patients' antibody levels declined three months after treatment, which is to be expected since all or most of the cancer has just been eliminated.
Over time, however, researchers found that in patients whose cancer recurred, their E7 antibody levels did not decrease as quickly as their counterparts. Importantly, this could be detected before the recurrence was discovered.
When it comes to evaluating E7 antibody levels, every patient is different. Physicians must look at the patient’s specific baseline level rather than compare their levels to an absolute level. Over time, if E7 levels increase, it indicates recurrence, according to the study.
Currently, patients with oropharyngeal cancer go in for post-treatment checkups every few months to monitor the status of the disease and see if there is recurrence. This biomarker has the potential to change that and make the monitoring process easier on the patient, as they could have their blood drawn near home, and come into clinic if the E7 levels rise.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
Predicting HPV+ Oropharyngeal Cancer Recurrence With Novel Biomarker
There is a need to find biomarkers that may help predict recurrence in HPV+ oropharyngeal cancer, says Matthew E. Spector, M.D.
//For side ad protocol